The Motley Fool Previous Page

Why Dendreon Shares Faltered Again

Sean Williams
August 9, 2013

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Dendreon Corporation (NASDAQ: DNDN), a biotechnology company focused on developing novel immunotherapeutic cancer solutions, fell as much as 24% after reporting disappoint second-quarter earnings results.

So what: For the quarter, Dendreon delivered $73.3 million in sales, which was 8% below what it reported at this time last year, and a narrower loss of $68.8 million, or $0.45 per sh